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Abstract
Background: As EPO treatment of chronic anemia of advanced renal disease is now the standard
of care we examined if such treatment may slow the progression of renal function decline.
Methods: Data of 18 pre-ESRD patients were analyzed retrospectively 12 months prior and
prospectively 12 months after the initiation of EPO. Mean creatinine was 5.0 ± 1.8 mg/dL (Mean ±
SEM) when starting EPO at a weekly dose of 5000 ± 500 units once the hematocrit was below 30
%. EPO dose was titrated monthly for a hematocrit between 33.0% and 37.0%. Metabolic
complications and hypertension were controlled.
Results: At month_0 the average blood pressure was 148/76 ± 5/4 mmHg and at month_12 it was
145/73 ± 6/3 mmHg (p = 0.75 by 2 tailed paired Student's t test). 12/18 patients were on an ACE-
i or ARB before month_0 and 14/18 were on it after (p = 0.71 by Fisher's 2 tailed exact test). The
average hematocrit rose from 26.9% ± 0.6 to 33.1 % ± 0.1. When linear regression analysis was
applied to pre- and post-EPO 1/creatinine data the mean rate of decline was -0.0140 ± 0.0119
(mean ± SD) and -0.0017 ± 0.0090 (non-parametric Wilcoxon matched pairs signed rank sum test:
Z value: -2.91; P = 0.004) respectively. 5/18 patients did not require dialysis 12 months after starting
EPO (month_0).
Conclusion: Treatment of the anemia of chronic renal failure with erythropoietin, when instituted
together with vigorous metabolic control may slow the rate of renal function decline.
Background
Chronic renal failure is often a progressive rather than a
stable process which most frequently leads to end stage
renal disease (ESRD). There are very few maneuvers that
can ameliorate the course of renal insufficiency such as
the use of ACE-inhibitors, aggressive blood pressure con-
trol or vigorous glucose control. As the renal function pro-
gressively declines complications of renal failure such as
acidosis, uremia or volume overload become more and
more significant and eventually may be the principal rea-
son for the initiation of renal replacement therapy. These
complications of chronic renal failure, however, can be
managed for awhile with medical therapy. We noted that
the control of anemia of renal failure not only manages
the complication of chronic renal failure but also slows
the rate of renal function decline or in some cases it arrests
the process. As the treatment of anemia of pre-ESRD
patients with EPO is now the standard of care we
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progression of renal function decline.
Methods
Study design
This is a prospective, observational-clinical cohort study
of patients treated for cohort anemia. Data were analyzed
to compare the rate of progression of renal disease based
on serum creatinine values before the initiation of human
recombinant erythropoietin (EPO) [Procrit® by Ortho Bio-
tech] and after.
Inclusion criteria
Adult patients who developed a renal disease who pro-
gressed to the stage requiring treatment of their anemia by
subcutaneous EPO. Patients had to have at least three
months' data prior to the EPO therapy followed by at least
three months' data after therapy was started in our outpa-
tient nephrology clinic at a tertiary referral center. Data of
patients of any renal disease with a severe renal failure
were examined including glomerulonephritides, lupus
nephritis, diabetic nephropathy and unknown renal
diseases.
Exclusion criteria
Transplant recipient status, acute renal failure or anemia
identified as other than secondary to chronic renal failure
were exclusion criteria.
Methods
Patients with severe renal failure were identified at the
time of initiating EPO treatment in a clinical setting. Data
of 35 such patients were examined and 18 qualified for
data analysis. Data were analyzed in a retrospective man-
ner 1 year prior and prospectively one year after the initi-
ation of EPO. The mean age of patients was 67.3 ± 0.05
(Mean ± SEM) years at the start of the observation, 2 were
African Americans and one was Hispanic, 6 patients were
women and 7 had type II diabetes mellitus. The exact
pathology for the renal failure was not known in the
majority of patients, but one was known to have poly-
cystic kidney disease. The patients' mean creatinine was
5.0 ± 1.8 mg/dL at the time of starting subcutaneous EPO
at a starting weekly dose of 5000 ± 500 units depending
on the degree of anemia when the patient's hematocrit
was less than 30 mg%. EPO dose was adjusted monthly to
keep the hematocrit between 33.0% and 37.0%. All
patients were monitored with monthly physical examina-
tion as well as laboratory tests that included hemoglobin,
hematocrit, iron saturation, Blood Urea Nitrogen, creati-
nine and electrolytes. Iron was supplemented by oral iron
preparations described to be taken daily but when the
iron saturation reached less than 20% then intravenous
iron dextran was given in an outpatient setting in divided
doses to reach 1 gm per course. Metabolic acidosis was
controlled to keep the "CO2" (bicarbonate) on the elec-
trolyte panel greater than 22 mmol/L by either oral
sodium bicarbonate or sodium citrate. Potassium was pri-
marily controlled by controlling the metabolic acidosis,
diuretics or occasionally by oral sodium polystyrene.
Blood pressure control was maximized with a preference
for an angiotensin converting enzyme inhibitor (ACE-i)
or angiotensin receptor blocking agent (ARB). A nephrol-
ogist saw all patients monthly.
End points
Patients were monitored and their data collected until
they required dialysis or death (there was none) or lost to
follow up (1/18) whose data were censored. Necessity for
dialysis was decided when patients started to have uremic
symptoms or metabolic complications that could no
longer be managed medically.
Results
5 of the 18 patients did not require dialysis at the end of
the 12 months period after starting EPO (month_0). At
month 0 the average blood pressure was 148/76 ± 5/4
(mean ± SEM) mmHg and at month_12 the mean blood
pressure was 145/73 ± 6/3 mmHg (p = 0.75 by 2 tailed
paired Student's t test). 12/18 patients were on an ACE-i
or ARB before month 0 and 14/18 were on it after (p =
0.71 by Fisher's 2 tailed exact test). After starting EPO the
average hematocrit rose from 26.9 ± 0.6 to 33.1 ± 0.1
where they were maintained. When linear regression anal-
ysis was applied to pre- and post-EPO 1/creatinine data
the mean rate of 1/creatinine decline was -0.0140 ±
0.0119 (mean ± SD) and -0.0017 ± 0.0090 (using the
non-parametric Wilcoxon matched pairs signed rank sum
test: Z statistical value of -2.91 which corresponds to a two
tailed P = 0.004) respectively. The slope of the creatinine
rise changed to a negative value in 6 of the 18 patients'
case with this treatment indicating actual reversal.
Discussion
Although treatment the anemic complication of renal fail-
ure has been available since the late 1980's when EPO
became available treatment of it was delayed perhaps
because of initial concerns that EPO treatment may actu-
ally worsen the progression of renal disease. This suspi-
cion was based on rat studies that indicated that perhaps
anemia has a nephro-protective effect and the correction
of it would accelerate renal injury [1,2]. However, in a
double-blind placebo-controlled clinical trial there was
no adverse renal effect demonstrated over a 12-week
period [3] as expressed by 1/creatinine versus time. Simi-
larly, in a 24-week prospective open-label study the rate of
decline in kidney function was not altered by the use of
EPO [4]. We also used 1/creatinine values as the index of
renal function instead of creatinine because of the linearPage 2 of 4
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rate as opposed to the pure creatinine values [5,6].
Lim at al. [7] who also compared the slopes of linear
regression lines of the renal function of 26 patients over
24 months found that neither EPO administration nor a
normal hematocrit had any adverse effect on the renal
function. Others [8] have also confirmed that normaliza-
tion of the hematocrit with EPO does not accelerate the
loss of the residual renal function.
Our findings indicate that the treatment of anemia of
chronic renal failure may prolong the renal survival. This
is consistent with others' findings. A pediatric study from
Germany by Krmar et al.[9] as well as by Kuriyama [10]
who compared treated and untreated patients had similar
results. When compared, the treated patients had a lower
rate of progression of the renal decline in both studies
albeit the number of patients in the pediatric study was 11
thus no statistical significance could be shown.
Recently, Jungers [11] also found that the rate of progres-
sion of renal failure is slower in patients who receive EPO
than those who do not with a delayed need for initiation
of dialysis.
The possibility of explanations is rather wide. One could
speculate better oxygen delivery to the ischemic tissues
may be responsible for this beneficial effect. This process
would lower the ischemic burden perhaps by beneficial
effects of EPO on endothelial dysfunction as evidenced by
thrombomodulin/ creatinine ratios when treated with
Figure 1
1/creatinine values before and after EPO treatment. The rate of progression of renal function decline as reflected by 
the linear regression lines slowed from -0.0140 dL/mg·month ± 0.0119 (mean ± SD) to -0.0017 dL/mg·month ± 0.0090 (non-
parametric Wilcoxon matched pairs signed rank sum test: Z statistical value of -2.91 which corresponds to a two tailed P = 
0.004) after starting EPO at Month 0.Page 3 of 4
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EPO [12]. Other mechanism could involve the suppres-
sion of hormones such as angiotensin and aldosterone,
both of which are known to have important roles in tissue
damage and fibrosis. Since captopril was shown [13] to
increase the effective renal plasma flow and renal blood
flow in anemic pre-dialysis patients and this effect could
no longer be observed when treated with EPO it is possi-
ble that the correction of anemia may involve these hor-
mones that act of the efferent arterial resistance or other
hemodynamic modulators. Other fibrosis promoting par-
ticipant substances could also include TGF-beta yet their
role and response to EPO remains to be shown. While this
is only an observational study from the clinical practice
with a relatively small number of patients it could point
towards the necessity for a larger prospective study
designed to answer the question raised here whether the
administration of EPO in the pre-ESRD population can
indeed reverse or halt a process of continuous renal
decline.
Conclusions
Treatment of the anemia of chronic renal failure with sub-
cutaneous erythropoietin, when instituted together with
the vigorous control of the metabolic complications of
chronic renal failure may slow the rate of renal function
decline and in some cases may even reverse the process of
renal function loss.
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